Back to home
DEALS & FUNDINGApril 8, 2026·5 min read
Biopharma M&A on Pace for $172B Record Year After Seven $1B+ Deals in 12 Days
A March 2026 surge saw seven billion-dollar-plus acquisitions in under two weeks, from Gilead-Tubulis to Biogen-Apellis. Analysts project total 2026 deal volume could reach $172B, surpassing the $111B spent across 32 deals in 2025.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.